Evolent Health (EVH) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evolent Health (EVH) PT Lowered to $33 at Cowen; Reiterates Outperform
August 8, 2017 7:42 AM EDTCowen lowered its price target on Evolent Health (NYSE: EVH) to $33.00 (from $35.00) while maintaining a Outperform rating following 2Q release. Reported revenues of $107.3M exceeded guidance, and consensus estimates, despite soft transformation sales. Adjusted EPS of ($0.13) was in-line with Street's expectations.
EVH... More
